Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- DRUG DESIGN
- 1 Progress and issues for computationally guided lead discovery and optimization
- PART I STRUCTURAL BIOLOGY
- PART II COMPUTATIONAL CHEMISTRY METHODOLOGY
- PART III APPLICATIONS TO DRUG DISCOVERY
- 12 Computer-aided drug design: a practical guide to protein-structure-based modeling
- 13 Structure-based drug design case study: p38
- 14 Structure-based design of novel P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease
- 15 Purine nucleoside phosphorylases as targets for transition-state analog design
- 16 GPCR 3D modeling
- 17 Structure-based design of potent glycogen phosphorylase inhibitors
- Index
- References
14 - Structure-based design of novel P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease
from PART III - APPLICATIONS TO DRUG DISCOVERY
Published online by Cambridge University Press: 06 July 2010
Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- DRUG DESIGN
- 1 Progress and issues for computationally guided lead discovery and optimization
- PART I STRUCTURAL BIOLOGY
- PART II COMPUTATIONAL CHEMISTRY METHODOLOGY
- PART III APPLICATIONS TO DRUG DISCOVERY
- 12 Computer-aided drug design: a practical guide to protein-structure-based modeling
- 13 Structure-based drug design case study: p38
- 14 Structure-based design of novel P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease
- 15 Purine nucleoside phosphorylases as targets for transition-state analog design
- 16 GPCR 3D modeling
- 17 Structure-based design of potent glycogen phosphorylase inhibitors
- Index
- References
Summary
INTRODUCTION
Approximately 170 million people worldwide are chronically infected with hepatitis C virus (HCV), a (+)-strand RNA virus of the Flaviviridae family, which is spread primarily by direct contact with human blood. HCV causes chronic liver disease, including cirrhosis and hepatocellular carcinoma. At present, HCV is a leading cause of death in HIV co-infected patients and is the most common indication for liver transplantation. In the United States alone, data from death certificates suggest that there are 10,000 to 12,000 deaths annually due to hepatitis C.
Unlike HIV, HCV can be “cured”; that is, patients can achieve a sustained virologic response (SVR), in which the virus remains undetectable after termination of therapy. The current standard of care for the most prevalent genotype 1 infection is a regimen of pegylated interferon (IFN) plus ribavirin for 48 weeks. Due to limited efficacy (only about half of genotype 1 patients are able to achieve SVR at twenty-four weeks post-therapy) and significant side effects (e.g., injection site inflammation, flu-like symptoms, depression, and anemia), many patients discontinue treatment. Thus, there is a significant need to improve efficacy, reduce the duration of treatment, and develop an IFN-free regimen with a more convenient route of administration.
DRUG DESIGN TARGET
Several promising antiviral targets for HCV have emerged in recent years. As with HIV, most efforts have focused on inhibiting the key viral enzymes (see Figure 14.1). Inhibitors of one such target, HCV NS3/4A, have perhaps shown the most dramatic antiviral effects.
- Type
- Chapter
- Information
- Drug DesignStructure- and Ligand-Based Approaches, pp. 209 - 214Publisher: Cambridge University PressPrint publication year: 2010
References
Hepatitis C – global prevalence (update). Weekly Epidemiology Record 1999, 74, 425–427.
; VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Gastroenterology 2004, 127, S62–S71.Google Scholar
; ; ; ; ; ; ; ; ; Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J. Hepatol. 2005, 42, 799–805.Google Scholar
In Management of Hepatitis C: 2002; National Institutes of Health, 2002. http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm.
; ; ; ; ; ; ; ; ; ; Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352, 1426–1432.Google Scholar
; Control of hepatitis C: a medicinal chemistry perspective. J. Med. Chem. 2005, 48, 1–20.Google Scholar
; virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Curr. Opin. Drug Discov. Devel. 2006, 9, 606–617.Google Scholar
; Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr. Med. Chem. 2005, 12, 2317–2342.Google Scholar
; ; ; Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 1993, 67, 3835–3844.Google Scholar
; ; ; Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74, 2046–2051.Google Scholar
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J. Med. Chem. 2004, 47, 1605–1608.Google Scholar
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; . Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 2006, 50, 899–909.Google Scholar
; ; ; ; ; ; ; ; ; Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. Int. Ed. Engl. 2003, 42, 1356–1360.Google Scholar
; Dynamics and Structure-based Design of Drugs Targeting the Critical Serine Protease of the Hepatitis C Virus – From a Peptidic Substrate to BILN 2061. Curr. Med. Chem. Antinfect. Agents 2005, 4, 111–132.Google Scholar
; ; ; ; ; ; ; ; ; ; Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 1998, 7, 837–847.Google Scholar
; ; ; ; Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999, 7, 1353–1363.Google Scholar
Merck Molecular Force Field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 1996, 17, 490–519.Google Scholar
Merck Molecular Force Field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J. Comput. Chem. 1996, 17, 520–552.Google Scholar
Merck Molecular Force Field. III. Molecular geometries and vibrational frequencies for MMFF94. J. Comput. Chem. 1996, 17, 553–586.Google Scholar
; Merck Molecular Force Field. IV. Conformational energies and geometries for MMFF94. J. Comput. Chem. 1996, 17, 587–615.Google Scholar
Merck Molecular Force Field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J. Comput. Chem. 1996, 17, 616–641.Google Scholar
; Distance Geometry and Molecular Conformation. New York, NY: John Wiley & Sons; 1988.
; ; Sampling and efficiency of metric matrix distance geometry: a novel partial metrization algorithm. J. Biomol. NMR 1992, 2, 33–56.Google Scholar
; ; ; An extensive test of 14 scoring functions using the PDBbind refined set of 800 protein-ligand complexes. J. Chem. Inf. Comput. Sci. 2004, 44, 2114–2125.Google Scholar
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J. Am. Chem. Soc. 2008, 130, 4607–4609.Google Scholar
; ; ; ; ; A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations. Anal. Biochem. 2008, 373, 1–8.Google Scholar
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 2003, 278, 49164–49170.Google Scholar
; , , , ; Bristol-Myers Squibb. Preparation of prolinamide peptides as hepatitis C virus inhibitors: WO 2005054430, 2005.
; ; ; ; ; ; ; ; Bristol-Myers Squibb Hepatitis C Virus Inhibitors: US 6,995,174, 2006.
; ; ; First Scale-Up to Production Scale of a Ring Closing Metathesis Reaction Forming a 15-Membered Macrocycle as a Precursor of an Active Pharmaceutical Ingredient. Org. Process Res. Dev. 2005, 9, 513–515.Google Scholar
; ; Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease. Synlett 1999, S1, 1000–1002.Google Scholar
; ; ; ; ; ; ; Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease. J. Med. Chem. 2006, 49, 567–574.Google Scholar